Henry Schein, Inc. (NASDAQ:HSIC) Stock Has Average Target Price of $93.27 According to Analysts

Shares of Henry Schein, Inc. (NASDAQ:HSIC) have received an average rating of “Moderate Buy” from the fifteen brokerages that are currently covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and nine have given a buy rating to the company. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is $93.27.

Several equities analysts recently commented on HSIC shares. Wall Street Zen upgraded shares of Henry Schein from a “hold” rating to a “buy” rating in a research note on Monday, August 17th. Barrington Research set a $104.00 price target on shares of Henry Schein in a research report on Wednesday, August 5th. UBS Group set a $94.00 price objective on shares of Henry Schein and gave the stock a “neutral” rating in a report on Wednesday, August 5th. Citigroup reaffirmed a “buy” rating and set a $112.00 price objective (up from $100.00) on shares of Henry Schein in a research report on Wednesday, August 5th. Finally, Piper Sandler upped their price objective on shares of Henry Schein from $91.00 to $95.00 and gave the company an “overweight” rating in a research report on Wednesday, July 29th.

Henry Schein Stock Performance

Shares of NASDAQ HSIC opened at $84.96 on Friday. The company has a quick ratio of 0.73, a current ratio of 1.32 and a debt-to-equity ratio of 0.60. The business’s 50 day moving average is $86.95 and its two-hundred day moving average is $82.64. The company has a market cap of $9.47 billion, a P/E ratio of 24.77, a P/E/G ratio of 1.53 and a beta of 0.84. Henry Schein has a 12 month low of $62.15 and a 12 month high of $92.18.

Henry Schein (NASDAQ:HSIC) last issued its quarterly earnings results on Tuesday, August 4th. The company reported $1.27 EPS for the quarter, topping analysts’ consensus estimates of $1.24 by $0.03. Henry Schein had a return on equity of 15.97% and a net margin of 2.96%. The company had revenue of $3.46 billion during the quarter, compared to analyst estimates of $3.37 billion. During the same period in the previous year, the company earned $1.10 earnings per share. The company’s quarterly revenue was up 6.7% compared to the same quarter last year. Henry Schein has set its FY 2026 guidance at 5.290-5.390 EPS. On average, equities analysts expect that Henry Schein will post 5.36 EPS for the current year.

Hedge Funds Weigh In On Henry Schein

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Southpoint Capital Advisors LP lifted its position in shares of Henry Schein by 28.0% in the 1st quarter. Southpoint Capital Advisors LP now owns 3,200,000 shares of the company’s stock worth $235,840,000 after acquiring an additional 700,000 shares during the period. Dimensional Fund Advisors LP increased its position in shares of Henry Schein by 2.0% during the first quarter. Dimensional Fund Advisors LP now owns 2,873,004 shares of the company’s stock valued at $211,734,000 after purchasing an additional 56,687 shares during the period. M.D. Sass LLC raised its stake in shares of Henry Schein by 2.9% in the first quarter. M.D. Sass LLC now owns 1,273,316 shares of the company’s stock valued at $93,843,000 after purchasing an additional 35,443 shares in the last quarter. Bank of America Corp DE raised its stake in shares of Henry Schein by 5.9% in the first quarter. Bank of America Corp DE now owns 1,221,585 shares of the company’s stock valued at $90,031,000 after purchasing an additional 68,593 shares in the last quarter. Finally, Defilade Capital Management L.P. raised its stake in shares of Henry Schein by 94.8% in the first quarter. Defilade Capital Management L.P. now owns 624,037 shares of the company’s stock valued at $45,992,000 after purchasing an additional 303,615 shares in the last quarter. 96.62% of the stock is currently owned by institutional investors.

About Henry Schein

Henry Schein, Inc (NASDAQ: HSIC) is a global provider of healthcare products and services serving dental and medical professionals, as well as veterinary practices and laboratories. The company distributes consumable supplies, equipment, pharmaceuticals, vaccines, and other products used in clinical and practice-management settings.

In addition to product distribution, Henry Schein provides technology solutions and value-added services designed to support clinical workflows, electronic health records, practice management, procurement, equipment installation, and technical support.